GENesis of actionable INSights to unlock disease & novel therapies

Are you a researcher struggling to extract disease-causing mechanisms and actionable targets for drug discovery from vast multi-dimensional omics data?

Find out more Schedule a call


Get access to a whole team for a fraction of the cost of hiring one person

INSiGENe delivers systems biology-driven bioinformatics as a service (BaaS) and biostatistics support for a wide range of therapeutics areas.

Find out more Schedule a call


Identifies novel therapeutic targets from human or mouse single cell mRNA expression data.

Decipher enables you to go from raw sequencing data to experimentally validated, novel therapeutic targets within 12 months.

Find out more Schedule a call

Here is what our clients have said about INSiGENe

“It has been a pleasure working with the INSiGENe team. Having the peace of mind that your data is being analysed properly and the results presented in a professional, publication-ready format is priceless. We were able to have insightful discussions on how to approach the analysis, and the data reports are easy to follow and very well explained, even for someone without-omics expertise. I hope to continue our ongoing collaboration”

Dr Livia Carvalho – Lion’s Eye Institute, Perth, Australia

“I have personal utilized INSiGENe services both in my academic and commercial roles across multiple omics using my own data and publicly available databases. INSiGENe analysis has been of exceptional quality and provided within the agreed time frames. Importantly, the data returned has been consistent with my experiments assuring me of its significance.  Alongside this, we have made several novel discoveries based on their analysis.

I highly recommend INSiGENe for your next bioinformatic project.”

Professor Terrance Johns (Professor of Paediatric Cancer Research, UWA and Head of Research Epigenes Australia)


Schedule your free discovery call here

Contact us at

© 2024 INSiGENe Ltd. Site maintained by NFIC Services  |  Privacy Policy.